c10c-G1V3
c10c-G1V3 is a BRAG2 binder with a Kd value of 7.37 μM. c10c-G1V3 binds to BRAG2, thereby disrupting its interaction with GluA2 and blocking GluA2 endocytosis and AMPAR subunit switching. c10c-G1V3 reduces glutamate-induced intracellular reactive oxygen species (ROS) accumulation and cell apoptosis (apoptosis). c10c-G1V3 decreases infarct volume in the transient middle cerebral artery occlusion model. c10c-G1V3 can be used in studies related to ischemic stroke.
For research use only. We do not sell to patients.
- Formula: C58H78N12O19
- Molecular Weight:1247.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All iGluR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
BRAG2 7.37 μM (Kd) |
In Vitro
c10c-G1V3 (1.5625-100 μg/mL; 60 s association, 120 s dissociation) binds to purified human BRAG2 (AA390-763) with a Kd value of 7.37 μM[1].
c10c-G1V3 (10 μM; 24 h) shows no cytotoxicity against HT22 cells[1].
c10c-G1V3 (0.1-10 μM; 24 h preincubation prior to OGD injury) protects HT22 cells against OGD-induced damage in a dose-dependent manner[1].
c10c-G1V3 (20 μM; 4 h) exhibits stronger membrane permeability than the unmodified 3Y peptide scaffold in HEK293T cells[1].
c10c-G1V3 (200 μM; 0-8 h) exhibits superior plasma stability in rat plasma, with a half-life >8 h[1].
c10c-G1V3 (0.1-10 μM; preincubated for 2 h prior to exposure to 5 mM glutamate for 24 h) protects HT22 cells against glutamate-induced excitotoxicity, maintaining a cell viability rate of 76.34% at high concentrations[1].
c10c-G1V3 (10 μM; 30 min preincubation prior to exposure to 5 mM glutamate for 24 h) significantly inhibits glutamate-induced ROS accumulation and alleviates intracellular oxidative stress in HT22 cells[1].
c10c-G1V3 (10 μM; preincubated for 2 h prior to exposure to 10 mM glutamate for 24 h) reduces glutamate-induced apoptosis of HT22 cells[1].
c10c-G1V3 (10 μM; preincubated for 2 h prior to exposure to 10 mM glutamate for 24 h) regulates the mitochondrial apoptosis pathway in HT22 cells, and alleviates glutamate-induced apoptosis by upregulating the expression of the anti-apoptotic protein Bcl-2 and downregulating the expression of the pro-apoptotic protein Bax and cleaved-caspase 3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT22 hippocampal neuronal cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Did not significantly affect HT22 cell viability, with survival rates exceeding 95%.
-
Cell Line:HT22 cells (oxygen-glucose deprivation injury model)
-
Concentration:0.1, 1 and 10 μM
-
Incubation Time:24 h preincubation before OGD injury
-
Result:Maintained HT22 cell viability at 75% at 0.1 μM.
Maintained HT22 cell viability at 76.08% at 1 μM.
Maintained HT22 cell viability at 85.97% at 10 μM.
Outperformed the reference compound Tat-GluA2-3Y at equivalent concentrations.
-
Cell Line:HT22 cells (glutamate-induced excitotoxicity model)
-
Concentration:0.1, 1 and 10 μM
-
Incubation Time:2 h preincubation before 5 mM glutamate exposure for 24 h
-
Result:Maintained HT22 cell viability at 70% at 0.1 μM.
Maintained HT22 cell viability at 70% at 1 μM.
Maintained HT22 cell viability at 76.34% at 10 μM (****p < 0.0001 vs glutamate control).
-
Cell Line:HT22 cells (glutamate-induced excitotoxicity model)
-
Concentration:10 μM
-
Incubation Time:2 h preincubation before 10 mM glutamate exposure for 24 h
-
Result:Reduced total HT22 cell apoptosis rate from 12.4% to 10.7%.
Showed reduced apoptotic nuclear condensation in c10c-G1V3-treated cells compared to glutamate-only controls via Hoechst 33342 staining.
-
Cell Line:HT22 cells (glutamate-induced excitotoxicity model)
-
Concentration:10 μM
-
Incubation Time:2 h preincubation before 10 mM glutamate exposure for 24 h
-
Result:Increased Bcl-2 expression to ~90% of control, compared to 50% of control after glutamate exposure.
Downregulated Bax and cleaved-caspase 3 expression.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (adult male, transient middle cerebral artery occlusion cerebral ischemia/reperfusion model)[1]
-
Dosage:8 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced infarct area by 9.4% compared to the tMCAO model group.
Showed no significant difference in infarct area compared to the positive control Tat-GluA2-3Y group.
Significantly improved neurological deficit scores compared to the model group.
Chemical Information
-
Molecular Weight 1247.31
-
Formula C58H78N12O19
-
Sequence
Cyclo(Tyr-Lys-Glu-Gly-Tyr-Asn-{Val(N-Me)}-Tyr-{Gly(N-Me)}-Glu)
-
Sequence Shortening
Cyclo(YKEGYN-{Val(N-Me)}-Y-{Gly(N-Me)}-E)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)